Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients

See more here


Bainbridge Health Is Harnessing Medication Utilization Data to Conserve Waste and Manage The Supply of Critical Care Drugs Used to Treat COVID-19 Patients
Bainbridge Health, a provider of medication safety and stewardship solutions, is utilizing data from its network of over 50 hospitals to help clinicians understand the impact of COVID-19 on critical care medications.   

See more here


Wellsheet Appoints Dr. Frederik Lindberg, MD, PhD, and Healthcare Executive as VP of Product Management
Former Flatiron Health executive Dr. Frederik Lindberg, MD, PhD joins Wellsheet management team to lead product management and transform the EHR experience for physicians.  

See more here


Halo Labs Launches Aura for Particle and Aggregate ID in Biotherapeutic Development 
Aura revolutionizes biologic stability analysis, enabling simple protein and non-protein aggregate identification in formulation development and analytical testing    

See more here


Melior Discovery Announces Partnership with SFA on Grant Directed to Covid-19
– SFA Therapeutics receives award from Ben Franklin Technology Partners –

– Melior Discovery selected as partner –

See more here


Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study

See more here


ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint   

See more here


Wellsheet Raises Series A Funding for Healthcare Workflow Platform to Reduce Time in the EHR and Physician Burnout 
Dr. John Glaser, former CIO of Partners, and Dr. Georgia Papathomas, former SVP of Johnson & Johnson, Join the Wellsheet
Board of Director   

See more here


Palvella Therapeutics Completes $45 Million Series C Financing
Investor Syndicate Comprised of Leading Biotech Investors  

Proceeds to Accelerate  Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome  

Top-Line Data Expected in Q4 2020 from Phase 2/3 Pivotal Study for Fast Track-Designated Lead Program Pachyonychia Congenita    

See more here


Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19

See more here